Nordson is a quality precision-machinery compounder. Its Q2 FY26 was a record quarter — sales $741M (+8%), adjusted EPS $2.86 (+18%) — and management raised full-year guidance, extending a clean four-beat earnings streakSEC 8-K· mai 2026. The chart shows the tightest, least-extended setup of the quality-industrial group — EMA20 > EMA50 > EMA200 neatly stacked, RSI a calm 54, price just 1.3% above EMA20 and ~6% below its 52-week high. The catch: a balance-sheet-clean Dividend King at 24x forward is fairly — not cheaply — priced, and TP1 sits right at the prior peak.
Nordson Corporation engineers precision dispensing, fluid-management, and test-and-inspection systems — the unglamorous but mission-critical equipment that lays down adhesives, sealants, coatings and biomaterials, and verifies that electronics and medical devices are built right. The company sells into deeply embedded niches where its installed base, consumables and service create a recurring, sticky revenue streamStockAnalysis· juin 2026.
The business runs across three segments: Industrial Precision Solutions (adhesive dispensing, packaging, polymer processing), Medical and Fluid Solutions (medical components, single-use plastics, biomaterials), and Advanced Technology Solutions (electronics test, inspection and precision dispensing for semis and PCBs). The moat is razor/razor-blade economics plus engineering specificity: once a Nordson dispense head is qualified on a customer's line, switching is costly and rare. That is what funds a 55% gross margin, a 25% operating margin and a 62-year dividend-raise streak — Nordson is a bona-fide Dividend King.
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $2.90B | +8% YoY (Q2) |
| EBITDA (TTM) | $876M | ~30% margin |
| Net Income (TTM) | $528M | Growing |
| Gross Margin | 55.2% | Excellent |
| Operating Margin | 25.5% | Strong |
| Net Margin | 18.2% | Healthy |
| ROE | 16.9% | Solid |
| Debt / Equity | 0.59 | Investment-grade |
| Current Ratio | 2.60 | Liquid |
| P/E (trailing) | 30.8x | Quality premium |
| Fwd P/E | 24.2x | Fair |
| Analyst Target | $310 – $319 | +8–11% upside |
This is a high-quality machine. A 55% gross margin and 25% operating margin on $2.9B of revenue, financed with a conservative 0.59 debt/equity and a 2.6 current ratio, is the financial signature of a wide-moat compounder. FY25 EBITDA margin printed ~31%, and the TTM is holding ~30%StockAnalysis· juin 2026. The valuation — 24x forward — is the honest caveat: this is a fair price for quality, not a bargain. The Street consensus sits at $310–$319, an 8–11% premium to spot, with a high estimate of $335StockAnalysis Forecast· juin 2026.
| Price | $288.21 |
| RSI (14) | 54.2 |
| EMA 20 | $284.46 |
| EMA 50 | $281.43 |
| EMA 200 | $261.75 |
| ATR (14) | $6.61 (2.3%) |
| Extension vs EMA20 | +1.32% |
| 52W High | $305.28 |
Textbook bullish structure with minimal extension. EMA20 ($284.46) > EMA50 ($281.43) > EMA200 ($261.75) — a clean, upward-sloping stack with price riding just 1.3% above the EMA20Yahoo Finance· live. RSI at 54.2 sits in the calm middle of the range — there is no overbought condition to unwind, which is exactly what you want before a breakout attempt. ATR of $6.61 (2.3%) is low, giving precise risk control. The whole thesis funnels into one level: $305.28, the 52-week high. A daily close above it on volume opens clean air toward the $322 measured target; failure there is the natural place to step aside.
The clean-flag check is unambiguous. EDGAR shows no equity dilution machinery for Nordson: no S-1, no equity ATM program, no convertible notes, no mandatory-convertible preferreds, and no 424B5 equity offerings. Share count is stable at 55.7MStockAnalysis· juin 2026. The only registration filings on record are a 2023 S-3ASR paired with 424B2 prospectus supplements in 2023–2024 — these are senior-note debt issuances (investment-grade bonds used to fund M&A), not equity dilutionSEC EDGAR· 2023–24.
A wide-moat, balance-sheet-clean compounder with a 62-year dividend streak. The real risks are valuation (fair, not cheap), a TP1 that sits at resistance, and late-cycle capex sensitivity — not balance-sheet or dilution risk.
Nordson's risk is almost entirely about price paid, not business quality. There is no dilution, no toxic financing, no cash-burn problem, and no leverage stress — the balance sheet is investment-grade. The two risks that actually matter are valuation (24x leaves little cushion for a miss) and the chart (TP1 sits at resistance). Both are managed by the trade plan below: a tight stop under the EMA structure and scaling out into the 52-week highStockAnalysis· juin 2026.
Buy a quality compounder on the cleanest setup of the group. A record Q2, a guidance raise to $11.30–$11.80 EPS, and a four-beat streak give the fundamentals momentum, while the chart offers a low-extension entry with EMAs neatly stacked. The math: from a $286.80 limit entry, risk to the $274.90 stop is $11.90; reward to the $304.60 TP1 is $17.80 — a 1.5 R/R [ (304.60 − 286.80) ÷ (286.80 − 274.90) = 1.50 ]. On a confirmed breakout above the 52-week high, TP2 at $322.50 stretches the reward to 3.0 R/R.
Horizon: swing (2–8 weeks). Scale out into TP1 at the 52-week high; trail the remainder only on a confirmed daily close above $305.28.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from Yahoo Finance, StockAnalysis.com, and SEC EDGAR. Accuracy is not guaranteed.